Showing 2501-2510 of 5623 results for "".
- Elizabeth Yeu, MD, and K. Peony Yu, MD, Appointed to Staar Surgical Board of Directorshttps://modernod.com/news/elizabeth-yeu-md-and-k-peony-yu-md-appointed-to-staar-surgical-board-of-directors/2478798/Staar Surgical announced the appointments of Elizabeth Yeu, MD, Partner, Virginia Eye Consultants, and K. Peony Yu, MD, retired Chief Medical Officer, FibroGen, to its Board of Directors, effective January 21, 2021. “The addition of Dr. Elizabeth Yeu and Dr. K. Peony Yu to our Board of Dir
- MeiraGTx Announces AAV-CNGA3 Granted Fast Track Designation by FDA for Treatment of Achromatopsiahttps://modernod.com/news/meiragtx-announces-aav-cnga3-granted-fast-track-designation-by-fda-for-treatment-of-achromatopsia/2478795/MeiraGTx Holdings announced that the FDA has granted Fast Track designation to its AAV-CNGA3 gene therapy product candidate for the treatment of achromatopsia (ACHM) caused by mutations in the CNGA3 gene. ACHM is an inherited retinal disease that severely limits a per
- Keeler Partners With Merakris Therapeutics, Developer of Biological Barrier Grafthttps://modernod.com/news/keeler-patners-with-merakris-therapeutics-developer-of-biological-barrier-graft/2478785/Keeler has announced its partnership with Merakris Therapeutics, which is developing commercially scalable biotherapeutic technologies derived from stem cells that promote homeostasis in damaged tissue. Terms of the deal were not disclosed. “We are excited. This partnership accelera
- Gemini Therapeutics Announces FDA Fast Track Designation Granted for GEM103 for Investigational Dry AMD Treatmenthttps://modernod.com/news/gemini-therapeutics-announces-fda-fast-track-designation-granted-for-gem103-for-investigational-dry-amd-treatment/2478737/Gemini Therapeutics announced that GEM103, the company’s investigational treatment for dry AMD, has been granted Fast Track designation by the FDA. Gemini is evaluating GEM103, a recombinant, human complement factor H (CFH), for its ability to address the multiple AMD pathobiologies in gene
- IACTA Pharmaceuticals and Pharmaleads to Develop the World’s First Epithelial Protective Drug Harnessing Endogenous Analgesia for the Topical Treatment of Acute and Chronic Ocular Painhttps://modernod.com/news/iacta-pharmaceuticals-and-pharmaleads-to-develop-the-worlds-first-epithelial-protective-drug-harnessing-endogenous-analgesia-for-the-topical-treatment-of-acute-and-chronic-ocular-pain/2478730/IACTA Pharmaceuticals and Pharmaleads announced they have entered into licensing agreements with IACTA acquiring global rights to Pharmaleads’ Dual Enkephalinase Inhibitors (DENKI), a novel class of non-opioid compounds for the treatment of acute and chronic ocular pain. “With
- Alcon Commercially Launches AcrySof IQ Vivity Extended Depth of Focus IOL in UShttps://modernod.com/news/alcon-launches-acrysof-iq-vivity-extended-depth-of-focus-iol-in-us/2478731/Alcon has commercially launched the AcrySof IQ Vivity IOL, which the company describes as the first and only non-diffractive extended depth of focus IOL in the United States. Vivity is a first-of-its-kind, non-diffractive extended depth of focus IOL with Alcon’s proprietary non-diffractiv
- SIFI Launches Dry Eye Disease Device Synfohttps://modernod.com/news/sifi-launches-dry-eye-disease-synfo/2478726/SIFI announced the launch of Synfo, a novel medical device for dry eye disease. The new hypotonic formulation is a synergistic blend of two polymers—sodium hyaluronate and xanthan gum—and two osmoprotectants, betaine and glycine. In addition to moisturizing and lubricating, Synfo is design
- Vision Innovation Partners Completes 17th Acquisition, Eyes of Yorkhttps://modernod.com/news/vision-innovation-partners-completes-17th-acquisition-eyes-of-york/2478708/Vision Innovation Partners announced that it has acquired Eyes of York, an ophthalmology practice in York, Pennsylvania. The acquisition strengthens Vision Innovation Partners’ presence in the
- UK Officials Defend Contingency Plan to Mix COVID-19 Vaccines in Rare Caseshttps://modernod.com/news/uk-officials-defend-contingency-plan-to-mix-covid-19-vaccines-in-rare-cases/2478710/According to a guidance update on December 31, the UK government will allow people to be given doses of different COVID-19 vaccines under certain circumstances, despite a lack of evidence about the extent of immunity offered by such mixing. The issue has sparked criticism after a report in Th
- Ocugen and Bharat Biotech to Co-Develop COVID-19 Vaccine for the US Markethttps://modernod.com/news/ocugen-and-bharat-biotech-to-co-develop-covaxin-covid-19-vaccine-for-the-us-market/2478692/Ophthalmic biopharma company Ocugen has signed a letter of intent to co-develop Bharat Biotech’s COVID-19 vaccine candidate, Covaxin, an advanced stage whole-viron inactivated vaccine candidate, for the United States market. Covaxin has been evaluated in approximately 1,000 subjects in pha